Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12196-12208

  Zhu, Mingyue ^a   Guo, Junli ^a,b   Li, Wei ^a   Lu, Yan ^a   Fu, Shigan ^a   Xie, Xieju ^a   Xia, Hua ^a   Dong, Xu ^a   Chen, Yi ^a   Quan, Ming ^b   Zheng, Shaojiang ^a   Xie, Keping ^b   Li, Mengsen ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AFP; HBx; Hepatocarcinogenesis; Liver cells; PI3K mTOR signaling

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN ACTIVATED PROTEIN KINASE B; CHEMOKINE RECEPTOR CXCR4; HEPATITIS B VIRUS X PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TRANSACTIVATOR PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENETIC TRANSFECTION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; ONCOGENE RAS; ONCOGENE SRC; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; GENETICS; LIVER; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; CELL LINE, TUMOR; HUMANS; LIVER; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANS-ACTIVATORS; TRANSFECTION;

EID: 84929211544     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2906     Document Type: Article

References (50)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J Clin. 2011; 61:69-90.
2. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: A meta-analysis. J Natl Cancer Inst. 2009; 101:1066-1082.
3. Keng VW, Tschida BR, Bell JB, Largaespada DA. Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. Hepatology. 2011; 53:781-790.
4. Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature. 1993; 361:742-745.
5. Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology. 1993; 192:346-350.
6. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol. 2011; 46:974-990.
7. Xiang WQ, Feng WF, Ke W, Sun Z, Chen Z, Liu W. Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J Hepatol. 2011; 54:26-33.
8. Arzumanyan A, Sambandam V, Clayton M, Choi SS, Xie G, Diehl AM, Yu DY, Feitelson MA. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res. 2012; 72:5912-5920.
9. Ogden SK, Lee KC, Barton MC. Hepatitis B viral transactivator HBx alleviates p53-mediated repression of a-fetoprotein gene expression. J Biol Chem. 2000; 275:27806-27814.
10. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response elementdirected transactivation. J Virol. 1995; 69:1851-1859.
11. Ekshyyan O, Anandharaj A, Nathan CA. Dual PI3K/mTOR inhibitors: Does p53 modulate response?. Clin Cancer Res. 2013; 19:3719-3721.
12. Yoo YG, Oh SH, Park ES, Cho H, Lee N, Park H, Kim DK, Yu DY, Seong JK, Lee MO. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem. 2003; 278:39076-39084.
13. Wang FZ, Fei HR, Lian LH, Wang JM, Qiu YY. Hepatitis B x-interacting protein induces HepG2 cell proliferation through activation of the phosphatidylinositol 3-kinase/Akt pathway. Exp Biol Med (Maywood). 2011; 236:62-69.
14. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology. 2004; 39:1683-1693.
15. Lee YI, Kang-Park S, Do SI, Lee YI. The Hepatitis B virus-X protein activates a phosphatidylinositol 3-kinasedependent survival signaling cascade. J Biol Chem. 2001; 276:16969-16977.
16. Hann HW, Fu X, Myers RE, Hann RS, Wan S, Kim SH, Au N, Xing J, Yang H. Predictive value of alpha-fetoprotein in the long-term risk of developing hepatocellular carcinoma in patients with hepatitis B virus infection-results from a clinic-based longitudinal cohort. Eur J Cancer. 2012; 48:2319-2327.
17. Hung TM, Hu RH, Ho CM, Chiu YL, Lee JL, Jeng YM, Shih DT, Lee PH. Downregulation of alpha-fetoprotein expression by LHX4: a critical role in hepatocarcinogenesis. Carcinogenesis. 2011; 32:1815-1823.
18. Li M, Li H, Li C, Wang S, Jiang W, Liu Z, Zhou S, Liu X, McNutt MA, Li G. Alpha-fetoprotein: A new member of intracellular signal molecules in regulation of the PI3K/AKT signaling in human hepatoma cell lines. Int J Cancer. 2011; 128:524-532.
19. Wang GL, Iakova P, Wilde M, Awad S, Timchenko NA. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004; 18:912-925.
20. Wiedmann M, Tamaki S, Silberman R, de la Monte SM, Cousens L, Wands JR. Constitutive over-expression of the insulin receptor substrate-1 causes functional up-regulation of Fas receptor. J Hepatol. 2003; 38:803-810.
21. He X, Zhu Z, Johnson C, Stoops J, Eaker AE, Bowen W, DeFrances MC. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res. 2008; 68:5591-5598.
22. Yang WJ, Chang CJ, Yeh SH, Lin WH, Wang SH, Tsai TF, Chen DS, Chen PJ. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology. 2009; 49:1515-1524.
23. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F, Clément B, Balabaud C, Chevet E, Laurent A, Couchy G, Letouzé E, Calvo F, Zucman-Rossi J. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012; 44:694-698.
24. Ghasemi R, Ghaffari SH, Momeny M, Pirouzpanah S, Yousefi M, Malehmir M, Alimoghaddam K, Ghavamzadeh A. Multitargeting and antimetastatic potentials of silibinin in human HepG-2 and PLC/PRF/5 hepatoma cells. Nutr Cancer. 2013; 65:590-599.
25. Suzuki K, Oneyama C, Kimura H, Tajima S, Okada M. Down-regulation of the tumor suppressor C-terminal Src kinase (Csk)-binding protein (Cbp)/PAG1 is mediated by epigenetic histone modifications via the mitogen-activated protein kinase (MAPK)/phosphatidylinositol 3-kinase (PI3K) pathway. J Biol Chem. 2011; 286:15698-15706.
26. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun. 2007; 359:716-722.
27. Yasinska IM, Gibbs BF, Lall GS, Sumbayev VV. The HIF-1 transcription complex is essential for translational control of myeloid hematopoietic cell function by maintaining mTOR phosphorylation. Cell Mol Life Sci. 2014; 71:699-710.
28. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004; 10:594-601.
29. Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature. 2006; 442:779-785.
30. Li MS, Li PF, Yang FY, He SP, Du GG, Li G. The intracellular mechanism of alpha-fetoprotein promoting the proliferation of NIH 3T3 cells. Cell Res. 2002; 12:151-156.
31. Li M, Zhu M, Li W, Lu Y, Xie X, Wu Y, Zheng S. Alphafetoprotein receptor as an early indicator of HBx-driven hepatocarcinogenesis and its applications in tracing cancer cell metastasis. Cancer Lett. 2013; 330:170-180.
32. Li M, Xie X, Fu S, Zhu M, Li G. Alpha-fetoprotein up-regulated the expression of c-Src in hepatoma cells is PTEN/AKT signaling pathway dependent or independent. J Clin Oncol. 2010; 28:e21061.
33. Chung TW, Lee YC, Ko JH, Kim CH. Hepatitis B virus X protein modulates the expression of PTEN by inhibiting the function of p53, a transcriptional activator in liver cells. Cancer Res. 2003; 63:3453-3458.
34. Arima T, Nakao K, Nakata K, Ishikawa H, Ichikawa T, Hamasaki K, Ishii N, Eguchi K. Transactivation of human alpha-fetoprotein gene by X-gene product of hepatitis B virus in human hepatoma cells. Int J Mol Med. 2002; 9:397-400.
35. Li M, Li H, Li C, Guo L, Liu H, Zhou S, Liu X, Chen Z, Shi S, Wei J, McNutt MA, Li G. Cytoplasmic alpha-fetoprotein functions as a co-repressor in RA-RAR signaling to promote the growth of human hepatoma Bel 7402 cells. Cancer Lett. 2009; 285:190-199.
36. Li M, Li H, Li C, Zhou S, Guo L, Liu H, Jiang W, Liu X, Li P, McNutt MA, Li G. Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. Int J Cancer. 2009; 124:2845-2854.
37. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 2000; 103:843-852.
38. Choi Y, Zhang J, Murga C, Yu H, Koller E, Monia BP, Gutkind JS, Li W. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene. 2002; 21:5289-5300.
39. Xu Z, Stokoe D, Kane LP, Weiss A. The inducible expression of the tumor suppressor gene PTEN promotes apoptosis and decreases cell size by inhibiting the PI3K/Akt pathway in Jurkat T cells. Cell Growth Differ. 2002; 13:285-296.
40. Kang-Park S, Im JH, Lee JH, Lee YI. PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells. Virus Res. 2006; 122:53-60.
41. Liu LP, Ho RL, Chen GG, Lai PB. Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma. Clin Cancer Res. 2012; 18:5662-5671.
42. Otsuka M, Aizaki H, Kato N, Suzuki T, Miyamura T, Omata M, Seki N. Differential cellular gene expression induced by hepatitis B and C viruses. Biochem Biophys Res Commun. 2003; 300:443-447.
43. Zhou MX, Watabe M, Watabe K. The X-gene of human hepatitis B virus transactivates the c-jun and alpha-fetoprotein genes. Arch Virol. 1994; 134:369-378.
44. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci. 1992; 303:157-159.
45. Tilghman SM, Belayew A. Transcriptional control of the murine albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci USA. 1982; 79:5254-5257.
46. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase. J Biol Chem. 2003; 278:31807-31813.
47. Wei W, Huang W, Pan Y, Zhu F, Wu J. Functional switch of viral protein HBx on cell apoptosis, transformation, and tumorigenesis in association with oncoprotein Ras. Cancer Lett. 2006; 244:119-128.
48. Zheng L, Gong W, Liang P, Huang X, You N, Han KQ, Li YM, Li J. Effects of AFP-activated PI3K/Akt signaling pathway on cell proliferation of liver cancer. Tumour Biol. 2014; 35:4095-4099.
49. Schimanski CC, Bahre R, Gockel I, Müller A, Frerichs K, Hörner V, Teufel A, Simiantonaki N, Biesterfeld S, Wehler T, Schuler M, Achenbach T, Junginger T, Galle PR, Moehler M. Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer. 2006; 95:210-217.
50. Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY. Connexin-43 can delay early recurrence and metastasis in patients with hepatitis B-related hepatocellular carcinoma and low serum alpha-fetoprotein after radical hepatectomy. BMC Cancer. 2013; 13:306.